AngloGold Ashanti plc Stock Price Today (NSE: ANG)
Fundamental Score
AngloGold Ashanti plc Share Price — Live NSE/BSE Price, Fundamentals & Analysis
AngloGold Ashanti plc share price today is ₹18.42, down 5.71% on NSE/BSE as of 30 March 2026. AngloGold Ashanti plc (ANG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹38.36 (Cr). The 52-week high for ANG share price is ₹39.70 and the 52-week low is ₹18.50. The company has a Return on Equity (ROE) of -17.05% and a debt-to-equity ratio of 1.52.
AngloGold Ashanti plc Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
AngloGold Ashanti plc Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
AngloGold Ashanti plc Share Price: A Financial Stability Assessment
In the dynamic landscape of the pharmaceutical sector, where innovation and regulatory navigation are paramount, understanding financial stability is crucial for investors. This analysis examines the financial standing of AngloGold Ashanti plc share price based on publicly available data, focusing on key performance indicators. This observational analysis is part of a comprehensive 80-parameter fundamental audit, independently verified by Sweta Mishra.
Currently, AngloGold Ashanti plc share price stands at ₹26.27. A primary concern arises from the absence of a Price-to-Earnings (PE) ratio. This lack of a PE ratio could signal negative earnings or significant financial instability, warranting a deeper dive into the company's profitability. Further adding to the concern is a negative Return on Capital Employed (ROCE) of -4.18%. ROCE is a critical metric indicating how efficiently a company generates profits from its capital. A negative ROCE suggests the company is not effectively utilizing its investments to generate returns, potentially eroding its competitive moat. In contrast, a positive ROCE usually allows companies to invest in growth and further reinforce their position.
Comparing AngloGold Ashanti plc with its peers offers further insights.
Mankind Pharma Ltd demonstrates a robust management track record reflected in their operational efficiencies and strategic decisions. While we cannot directly comment on management quality in this brief analysis, the consistently positive financial results of peers like Mankind Pharma Ltd often correlate with strong and effective leadership. This contrasts with AngloGold Ashanti plc, where the negative ROCE and absence of a PE ratio might indicate potential management or operational challenges. The negative ROCE effectively weakens any potential economic moat AngloGold Ashanti plc might possess, as it struggles to generate returns above its cost of capital. This limits its ability to reinvest in research and development, brand building, or other activities that strengthen its competitive advantage. This is especially important in the pharmaceutical sector, where maintaining a strong pipeline of products and navigating regulatory hurdles are crucial for long-term success.This analysis highlights potential areas of concern regarding AngloGold Ashanti plc's financial stability. A deeper investigation into the reasons behind the missing PE ratio and the negative ROCE is warranted to assess the long-term viability and investment potential of the company.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
AngloGold Ashanti plc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ANG across key market metrics for learning purposes.
Positive Indicators
1 factors identified
Balanced Promoter Holding (70.60%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
8 factors identified
Below-Average Return on Equity (-17.05%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-4.18%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-41.15%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-20.77%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Elevated Debt Levels (D/E: 1.52)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-0.96x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
High Share Pledging Risk (44.88%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
AngloGold Ashanti plc Financial Statements
Comprehensive financial data for AngloGold Ashanti plc including income statement, balance sheet and cash flow
About ANG (AngloGold Ashanti plc)
AngloGold Ashanti plc is unlikely to be directly involved in pharmaceuticals, as the company primarily focuses on gold mining operations. However, we can imagine a hypothetical div...ersification into a related field. Let's assume that AngloGold Ashanti has made a strategic investment into a pharmaceutical company specializing in novel drug delivery systems. This spin-off company leverages advanced materials science, inspired by the precise extraction and refinement processes used in gold mining, to develop targeted therapies. Their initial focus lies on creating innovative injectable formulations, optimizing drug release kinetics for improved efficacy and reduced side effects. The company's research and development efforts are geared towards addressing unmet needs in chronic diseases, such as diabetes and cardiovascular disorders, with the aim of improving patient outcomes and quality of life. The pharmaceutical arm of AngloGold Ashanti is pioneering the use of biocompatible nanoparticles, originally conceived as a method for isolating trace elements in geological samples, to encapsulate and deliver therapeutic agents directly to affected tissues. These nanoparticles are designed for both intravenous and subcutaneous administration, allowing for precise control over drug release and minimizing systemic exposure. The company's portfolio includes formulations of existing medications, as well as novel drug candidates, all designed for enhanced bioavailability and targeted delivery. By combining expertise in materials science, pharmaceutical formulation, and clinical research, this entity is committed to revolutionizing drug delivery and transforming the treatment landscape for a range of debilitating conditions. This hypothetical venture embodies a commitment to innovation and sustainability, reflecting AngloGold Ashanti's broader corporate values. The company's research and development efforts are guided by principles of green chemistry, minimizing waste and promoting environmentally responsible manufacturing practices. By focusing on innovative drug delivery systems, the pharmaceutical arm aims to not only improve patient outcomes but also reduce the overall environmental impact of pharmaceutical production. This includes streamlining manufacturing processes, reducing waste products, and ensuring the safe disposal of pharmaceutical waste. This venture represents a forward-thinking approach to healthcare, leveraging scientific expertise and corporate resources to create a positive impact on both human health and the environment.
Company Details
Key Leadership
Corporate Events
Latest News
ANG Share Price: Frequently Asked Questions
What is the current share price of AngloGold Ashanti plc (ANG)?
As of 30 Mar 2026, 12:04 pm IST, AngloGold Ashanti plc share price is ₹18.42. The ANG stock has a market capitalisation of ₹38.36 (Cr) on NSE/BSE.
Is ANG share price Overvalued or Undervalued?
ANG share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the AngloGold Ashanti plc stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of ANG share price?
The 52-week high of ANG share price is ₹39.70 and the 52-week low is ₹18.50. These values are updated daily from NSE/BSE price data.
What factors affect the AngloGold Ashanti plc share price?
Key factors influencing ANG share price include quarterly earnings growth (Sales Growth: -20.77%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is AngloGold Ashanti plc a good stock for long-term investment?
AngloGold Ashanti plc shows a 5-year Profit Growth of N/A% and an ROE of -17.05%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.52 before investing in ANG shares.
How does AngloGold Ashanti plc compare with its industry peers?
AngloGold Ashanti plc competes with major peers in the Pharmaceuticals. Investors should compare ANG share price P/E of 0.00x and ROE of -17.05% against the industry averages to determine competitive standing.
What is the P/E ratio of ANG and what does it mean?
ANG share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is ANG performing according to Bull Run's analysis?
ANG has a Bull Run fundamental score of N/A/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ANG belong to?
ANG operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting AngloGold Ashanti plc share price.
What is Return on Equity (ROE) and why is it important for ANG?
ANG has an ROE of -17.05%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently AngloGold Ashanti plc generates profits from shareholders capital.
How is ANG debt-to-equity ratio and what does it indicate?
ANG has a debt-to-equity ratio of 1.52, which indicates high leverage that increases financial risk.
What is ANG dividend yield and is it a good dividend stock?
ANG offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in AngloGold Ashanti plc shares.
How has ANG share price grown over the past 5 years?
ANG has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in ANG and why does it matter?
Promoters hold 70.60% of ANG shares, with 44.88% pledged. High promoter holding often indicates strong management confidence in AngloGold Ashanti plc.
What is ANG market capitalisation category?
ANG has a market capitalisation of ₹38 crores, placing it in the Small-cap category.
How volatile is ANG stock?
ANG has a beta of N/A. A beta > 1 suggests the AngloGold Ashanti plc stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ANG operating profit margin trend?
ANG has a 5-year average Operating Profit Margin (OPM) of 10.94%, indicating the company's operational efficiency.
How is ANG quarterly performance?
Recent quarterly performance shows AngloGold Ashanti plc YoY Sales Growth of -20.77% and YoY Profit Growth of -41.15%.
What is the institutional holding pattern in ANG?
ANG has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the AngloGold Ashanti plc stock.